{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-102673","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.755892+00:00","generated_at":"2026-05-17T02:13:09.710049+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715","bullets":["CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.","CFO Daniel Schneiderman base salary increased to $391,000; target bonus at 40%.","Stock options granted: CEO 493,341 shares, CFO 317,266, employees 352,266 total.","Board Chair annual cash compensation reduced from $100K to $35K; consulting fees cut to $1/quarter.","Non-employee directors each receive 42,913 share options; Prof. Steinman gets one-time 200,000 share option."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-102673","json":"https://secwatch.observer/filing/0001213900-25-102673.json","markdown":"https://secwatch.observer/filing/0001213900-25-102673.md","text":"https://secwatch.observer/filing/0001213900-25-102673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/0001213900-25-102673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/ea0262506-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:13:09.710049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}